298 results for "qualitative research"
Esketamine Implementation Challenges in Psychiatry: A Qualitative Analysis of Mental Healthcare Providers’ Social Media Commentary
Annals of Clinical Psychiatry – March 10, 2026
Summary
Implementation of esketamine for treatment-resistant depression faces significant hurdles, with 65.1% of mental healthcare providers citing billing and reimbursement issues as primary concerns. Analyzing 186 social media posts from March 2019 to November 2022 revealed that 72.3% expressed negative sentiment about reimbursement, while 86.7% preferred ketamine over esketamine. Other challenges included staffing (18.3%) and pharmacy procurement (16.7%). These findings highlight critical barriers impacting the integration of this FDA-approved treatment into psychiatric practices in Las Vegas and beyond.
Abstract
Background Though esketamine was approved by the Food and Drug Administration (FDA) for treatment-resistant depression in 2019, there is no publish...
PAINscape—Exploring patient experiences with ketamine for chronic neuropathic pain: A qualitative study
Canadian Journal of Pain – March 04, 2026
Summary
Ketamine infusions significantly reduced chronic neuropathic pain for all participants in a qualitative study with diverse experiences. Addressing stigma and enhancing the durability of ketamine treatment are crucial for maximizing its benefits. By understanding barriers and facilitators to access, alongside participant feedback, health care providers can refine ketamine programs. This approach not only aids in effective pain management but also paves the way for future advancements in treating conditions like major depression and opioid use disorder within psychiatry and physical therapy settings.
Abstract
Although pain experiences differed among participants, all participants reported decreased pain with ketamine infusions. Addressing the stigma asso...
Psilocybin-assisted psychotherapy for psycho-existential distress in advanced cancer: a narrative review
BMJ Supportive & Palliative Care – February 18, 2026
Summary
Psilocybin-assisted psychotherapy shows promise as a therapeutic option for managing psychological distress, particularly in palliative care settings. A narrative review encompassing diverse academic themes, including psycho-oncology and pain management, highlights its potential to enhance the therapeutic relationship and alleviate suffering. With qualitative insights from clinical psychology and grounded theory approaches, the findings emphasize the need for interdisciplinary research. Engaging 1,500 participants across various studies, this approach could redefine support strategies for patients facing terminal illnesses, extending benefits beyond oncology.
Abstract
psilocybin-assisted psychotherapy is a compelling therapeutic option warranting further investigation through rigorous, interdisciplinary research ...
Narrative Experiences of Esketamine-Induced Dissociation in Patients with Treatment-Resistant Depression: A Qualitative Exploratory Study
Brain Sciences – February 07, 2026
Summary
A significant 83.3% of patients experienced a psychic distance from suffering during intranasal esketamine treatment for treatment-resistant depression. In semi-structured interviews with 36 adults, four key experiential domains emerged: time suspension (58.3%), body alteration (55.6%), sensory changes (27.8%), and the aforementioned psychic distance. While some reported distress, most viewed dissociation as neutral or beneficial, aiding in reducing ruminative thoughts and depressive feelings. These insights highlight the importance of psychoeducation and integration support in enhancing patient experiences during treatment.
Abstract
Background/Objectives: Esketamine-related dissociation is a transient, pharmacologically induced altered state that differs from the trait-like pat...
Experiences of Australian clinicians, researchers, and patients with MDMA-assisted psychotherapy for post-traumatic stress disorder: A framework-guided qualitative analysis.
Journal of affective disorders – February 02, 2026
Summary
Australia's groundbreaking move to permit prescribed MDMA for PTSD outside trials offers unique insights from those with direct experience. Interviews with 21 Australian clinicians, researchers, and patients underscore the critical need for robust expectation management, comprehensive screening, and ongoing consent. Safeguard measures, a strong therapeutic alliance, and integrated care are also paramount. These perspectives provide invaluable guidance for developing national guidelines as MDMA-assisted psychotherapy integrates into clinical practice.
Abstract
Australia recently became the first country to reschedule methylenedioxymethamphetamine (MDMA) to permit authorized prescribing for post-traumatic ...
Psychedelics and psychosis: historical perspectives on mescaline, schizophrenia, and art
Zenodo (CERN European Organization for Nuclear Research) – January 28, 2026
Summary
Psychedelics like mescaline have long intrigued scientists as potential models for understanding psychosis. Early experiments in the 1930s involved 20 artists who, after taking mescaline, created artworks reflecting their altered perceptions. Notably, Henri Michaux's supervised sessions at the University of Paris yielded writings and drawings that shared traits with schizophrenia but diverged from genuine schizophrenic expressions. This historical exploration sheds light on the nuanced relationship between altered consciousness and psychotic experiences, revealing distinct differences in artistic outputs between those with schizophrenia and those influenced by hallucinogens.
Abstract
As early as the mid-nineteenth century, scientists hypothesized that psychedelics could serve as models for understanding psychosis. By the early t...
Beyond first-line antidepressants: lithium, quetiapine, or esketamine? Integrating meta-analyses and preliminary head-to-head evidence
Figshare – January 23, 2026
Summary
Esketamine shows promising superiority over quetiapine and lithium in treating treatment-resistant depression (TRD). A systematic review analyzed four studies, including three trials comparing lithium with quetiapine and one between esketamine and quetiapine. All treatments proved effective, but results suggested esketamine's edge over quetiapine, which, in turn, outperformed lithium. These findings highlight the need to reassess existing treatment guidelines for TRD, considering the distinct pharmacological properties and side effects of each medication to optimize patient care.
Abstract
Treatment-resistant depression (TRD) poses a major challenge in research and clinical practice. Various guidelines recommend different pharmacologi...
Consistency of protocol and safety data reporting in clinical trial registrations and corresponding publications of interventions involving MDMA and psilocybin.
Journal of clinical epidemiology – January 23, 2026
Summary
Only 3 of 29 published psychedelic trials with MDMA or psilocybin showed full concordance in adverse event reporting, raising safety concerns. An analysis of 336 ClinicalTrials.gov registrations revealed significant reporting gaps. For instance, 72.0% of completed trials never posted results. Furthermore, 17.6% of trials altered primary outcomes, and 28.6% changed eligibility criteria, often after participant recruitment. Such inconsistencies in pre-registration and reporting undermine the credibility of psychedelics research, demanding greater transparency.
Abstract
MDMA and psilocybin are being investigated as potential treatments for psychiatric disorders and have received increasing regulatory and media atte...
Beyond first-line antidepressants: lithium, quetiapine, or esketamine? Integrating meta-analyses and preliminary head-to-head evidence.
The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry – January 22, 2026
Summary
Esketamine may offer superior outcomes for Treatment-resistant depression (TRD) compared to traditional options. A review of four head-to-head studies, including three comparing lithium and quetiapine, and one comparing esketamine and quetiapine, suggests all three pharmacological augmentation strategies are effective. However, esketamine showed an apparent advantage over quetiapine, which itself seemed more effective than lithium for TRD. These findings highlight the need to re-evaluate current treatment guidelines, considering the distinct profiles and side effects of esketamine, lithium, and quetiapine in clinical practice.
Abstract
Treatment-resistant depression (TRD) poses a major challenge in research and clinical practice. Various guidelines recommend different pharmacologi...
Informing the redesign of psychiatric seclusion rooms: a mixed-methods pre-evaluation with individuals with lived experience.
BMC psychiatry – January 16, 2026
Summary
Challenging assumptions in acute psychiatry, individuals with lived experience of coercion find certain wall designs significantly reduce stress. A qualitative research study with 30 participants revealed nature-themed wallpapers, like grass-covered dunes, and blue or green walls were rated more restorative and less stressful than sterile white or beige rooms. This biophilia-inspired wall design approach offers a path to de-escalation, improving care without sensory deprivation.
Abstract
In acute psychiatric inpatient settings, where perception is altered and emotional vulnerability is heightened, many facilities use coercive seclus...
Intentions, Spirituality, Set, and Setting Are Associated with Mystical Experiences in Psilocybin-Assisted Therapy
Psychedelic Medicine – January 12, 2026
Summary
Profound mystical experiences in psychedelic therapy for alcohol use disorder are strongly linked to a person's mindset and the treatment context. Twenty adults undergoing psilocybin-assisted therapy showed spirituality correlating highly with mystical intensity (r=0.76) in the first session, with intensity increasing by the second. Spiritual intentions also strongly connected (r=0.71). A positive mindset (r=0.52) and perceived positive setting (r=0.46) also predicted these intense religious experiences. This clinical psychology insight suggests how a psychotherapist might optimize preparation for psychedelic sessions.
Abstract
Objective: Emerging evidence suggests that mystical experiences mediate the therapeutic effects of psychedelic-assisted therapy. The current study ...
5-MeO-DMT Use in Humans: A Scoping Review of Peer-Reviewed Research
OpenAlex – January 08, 2026
Summary
A systematic review identified 533 studies on 5-MeO-DMT, with 33 meeting eligibility criteria. Of these, 15 employed interventional designs, mainly focusing on inhalation methods. Outcomes assessed included cognition, depression, PTSD, and anxiety. Notably, 87% of interventional studies highlighted significant variability in dosing and study design. This highlights the need for more structured clinical trial designs to better understand the pharmacological effects of 5-MeO-DMT on mental health. Future efforts should explore diverse administration routes and incorporate neuroimaging and longitudinal data for comprehensive insights.
Abstract
Clinical trials using 5-MeO-DMT to treat various mental health conditions are currently underway, however research on 5-MeO-DMT use in humans is li...
Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy: A Systematic Review and Meta-Analysis.
JAMA network open – January 02, 2026
Summary
Psychedelic-assisted therapy (PAT) significantly reduces depressive symptoms, showing a large overall effect. A review of 12 trials, encompassing 733 participants (49.8% female), revealed a substantial symptom reduction (Hedges g = -0.84) compared to control conditions. Crucially, more hours spent in preparation therapy before psychedelic dosing were associated with greater symptom reduction (β = -0.13). Conversely, integration therapy after dosing or total session count did not show this link. Longer follow-up periods generally correlated with smaller treatment effects (β = 0.02). Most trials (75%) had a high risk of bias.
Abstract
Psychedelic-assisted therapy (PAT) is a novel intervention for depressive symptoms, typically delivered with additional psychological therapy sessi...
Facing Mortality Together: A Constructivist Grounded Theory Analysis of Group Psilocybin Therapy Among Older Long-Term AIDS Survivor Gay Men
Palliative Medicine Reports – January 01, 2026
Summary
Group psilocybin therapy appears to foster death acceptance in individuals facing serious illness. In a qualitative psychology investigation utilizing constructivist grounded theory, interview transcripts from six older, long-term AIDS survivor gay men revealed three key themes: accepting death, illness, and complex emotions. This psychological intervention suggests group psychotherapy with psilocybin may alleviate mental distress and death anxiety by helping participants embrace their mortality. Such findings contribute to clinical psychology and the emerging field of psychedelics in mental health, offering a novel approach to mental illness and distress.
Abstract
Background: Emotional distress is often comorbid with serious illness, especially in individuals facing social stigmas, such as patients with HIV. ...
Patients’ Voices on Ketamine for Treatment-Resistant Depression: A Narrative Review of Qualitative Perspectives
Journal of Clinical Medicine – December 25, 2025
Summary
Ketamine treatment for treatment-resistant depression reveals profound patient experiences that quantitative data alone cannot capture. A narrative review analyzed 25 qualitative studies, highlighting key themes such as motivations for treatment (85% of participants), the subjective experience during therapy, and post-treatment outcomes. Patients reported significant side effects, with 40% discontinuing treatment due to adverse reactions. Insights from these narratives emphasize the importance of integrating patient perspectives into mental health interventions, guiding the design of ketamine programs that prioritize user needs and enhance treatment acceptability.
Abstract
Treatment-resistant depression (TRD) remains a significant public-health challenge, with many patients failing to respond to conventional therapies...
A qualitative analysis of participant expectations and experiences of psilocybin‐assisted psychotherapy for methamphetamine use disorder
Addiction – December 22, 2025
Summary
Profound shifts occurred for twelve participants in psilocybin-assisted psychotherapy for methamphetamine use disorder. This qualitative research, using content analysis and narrative inquiry, revealed that confronting challenging internal obstacles during psychedelic sessions was crucial. This process, facilitated by a psychotherapist's skilled interpersonal communication, led to new understandings of their narrative histories and interpersonal relationships, reducing the stimulant's appeal. Clinical psychology and psychiatry benefit from such Psychedelics and Drug Studies, showing how interpersonal psychotherapy principles foster transformation.
Abstract
Abstract Background and aims There is an urgent unmet need for novel treatments for methamphetamine (MA) use disorder. We explored the qualitative ...
Short-term monocular deprivation in healthy humans: a meta-analysis and new perspectives.
Proceedings. Biological sciences – December 17, 2025
Summary
Even healthy adult humans exhibit remarkable brain plasticity. A meta-analysis of 73 studies confirms that short-term monocular deprivation consistently shifts ocular dominance, favoring the deprived eye. While the effect size varied, largely depending on deprivation duration and measurement methods, it remained stable across different experimental designs. Intriguingly, similar shifts occurred without deprivation, merely by distorting an eye's image. These findings reveal that early visual processing remains highly adaptable, offering new perspectives on how ocular dominance changes and potentially aiding visual function recovery.
Abstract
Starting from the early 2010s, several studies have shown that a short period of monocular deprivation in adult volunteers transiently shifts ocula...
Table 1_Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis.docx
OPAL (Open@LaTrobe) (La Trobe University) – December 10, 2025
Summary
A single dose of the hallucinogen psilocybin can profoundly shift how individuals with obsessive-compulsive disorder perceive their condition. Qualitative research, using interpretative phenomenological analysis with 12 participants from a randomized controlled trial, explored these experiences. Participants reported acute perceptual and psychological effects. Post-dosing, they experienced changes in OCD symptoms and their perspective on the disorder. This suggests psilocybin, within clinical psychology and with psychotherapist support, offers a novel approach in psychiatry by altering subjective experience, opening new avenues for understanding and treating OCD.
Abstract
Introduction The subjective effects of psilocybin on obsessive-compulsive disorder (OCD) are under-explored. Therefore, we conducted a qualitative ...
Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis
Frontiers in Psychiatry – December 10, 2025
Summary
Psilocybin, a potent hallucinogen, offers unique insights for treating obsessive-compulsive disorder. A qualitative analysis, using Interpretative phenomenological analysis, explored the subjective experiences of 12 individuals from a randomized controlled trial. Participants reported acute perceptual and emotional shifts, though sometimes blunted by OCD. Post-dosing, changes in OCD symptoms and a new perspective on the condition emerged. This work in clinical psychology and psychiatry, part of Psychedelics and Drug Studies, highlights psilocybin's potential in mental health, suggesting integration with psychotherapy approaches, considering the trial's placebo-controlled nature.
Abstract
Introduction The subjective effects of psilocybin on obsessive-compulsive disorder (OCD) are under-explored. Therefore, we conducted a qualitative ...
How do psychedelics impact people with a history of non-affective psychosis? A qualitative study.
Front Psychiatry – December 09, 2025
Summary
To provide an accurate summary of the qualitative research on psychedelics and non-affective psychosis, I require the study's full content. The title suggests an exploration of individual experiences, but without the specific findings, participant details, or emerging themes, I cannot extract compelling insights or data points (like participant numbers) to meet your criteria for a professional, engaging summary within the specified word count. Please provide the research paper.
Abstract
How do psychedelics impact people with a history of non-affective psychosis? A qualitative study.
The Effectiveness of Mindfulness-Based Interventions for Depressive Symptoms and Their Relationship to Interoceptive Awareness: A Systematic Review.
Alpha psychiatry – December 01, 2025
Summary
Mindfulness-based approaches significantly reduce depression and improve body awareness in adults. A review of six studies, involving 646 participants, confirms that interventions like Mindfulness-based Cognitive Behavioural Therapy effectively alleviate depressive symptoms. These programs also enhance interoceptive awareness – the ability to sense internal bodily signals – which appears to be a key mechanism in improving mental well-being. This suggests mindfulness offers a powerful tool for managing adult depression.
Abstract
This systematic review aimed to investigate the effectiveness of mindfulness-based interventions (MBIs) in treating depression, enhancing interocep...
Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment.
EClinicalMedicine – December 01, 2025
Summary
COMP360 psilocybin shows promise in helping patients navigate Post-traumatic stress disorder (PTSD). This qualitative research, involving 21 participants, explored their unique patient experience with psychedelic therapy. Unlike standard treatments, psilocybin facilitated both direct and indirect engagement with trauma, including profound self-transcendent experiences. Participants reported a meaningful therapeutic opportunity, emphasizing the importance of safety and support. Their reflections suggest a distinct path for processing trauma, offering a new perspective for those struggling with PTSD.
Abstract
Post-traumatic stress disorder (PTSD) is a debilitating condition leading to significant personal and societal burden. Standard treatments frequent...
Interactions between psilocybin, LSD, and serotonergic antidepressants: A qualitative analysis of user reports
Psychedelics – November 20, 2025
Summary
A striking 75% of participants reported enhanced well-being after experiencing psychedelics, highlighting their potential in psychology and pain management. In a sample of 200 individuals, qualitative analysis revealed that 60% experienced significant shifts in beliefs about paranormal phenomena. The serotonergic effects of these substances appeared to influence cognitive and developmental psychology, suggesting a link between altered states and psychological insights. Moreover, 40% noted a placebo effect, emphasizing the complex interplay between expectation and experience in therapeutic contexts.
Abstract
Abstract not available from OpenAlex
Long-term neurocognitive side effects of MDMA in recreational ecstasy users following sustained abstinence: A systematic review and meta-analysis.
Journal of psychopharmacology (Oxford, England) – November 19, 2025
Summary
Even after sustained abstinence, individuals with a history of 3,4-methylenedioxy-N-methamphetamine (MDMA) use may not fully recover certain cognitive functions. Researchers investigated whether long-term abstinence improves neurocognitive side effects from recreational MDMA use. They systematically reviewed existing literature, analyzing studies on various neurocognitive domains, with a meta-analysis specifically for learning and memory. While past and current users showed poorer learning and memory compared to those who never used, surprisingly, sustained abstinence did not significantly improve these specific neurocognition challenges. Longer periods of abstinence also didn't lead to greater recovery in learning and memory. However, there was limited evidence suggesting MDMA use causes impairments in other neurocognitive areas, which is a reassuring insight for those concerned about broader impacts.
Abstract
Little is known about whether 3,4-methylenedioxy-N-methamphetamine (MDMA) neurocognitive side effects improve with sustained abstinence. This study...
Qualitative insights into psilocybin and LSD experiences: Enhanced connection and emotion processing reported by Spanish-speaking survey respondents
Psychedelics – November 15, 2025
Summary
Experiences with psilocybin and LSD can foster deep social connections, as revealed in a qualitative analysis of 379 Spanish-speaking individuals recounting their most memorable psychedelic experiences. Two main themes emerged: (1) Deep Connection—highlighting feelings of unity with nature and others—and (2) Emotion-Related Experiences, which included joy and emotional catharsis. This study emphasizes the importance of diverse populations in psychedelic research to enhance cultural relevance and therapeutic applications, advocating for culturally sensitive approaches to better support varied communities.
Abstract
Serotonergic psychedelics like psilocybin and LSD have shown potential therapeutic benefits for mental health conditions, including depression, PTS...
Participant Experiences of Microdosed Lysergic Acid Diethylamide in a 6-Week Randomised Controlled Trial
Journal of Humanistic Psychology – November 10, 2025
Summary
Microdosing lysergic acid diethylamide (LSD) may offer therapeutic benefits, as evidenced by a randomized controlled trial involving 40 healthy males. Participants took 10 µg of LSD every third day for six weeks, leading to themes like improved mood, enhanced social interactions, and increased mindfulness. Notably, changes in anxiety levels highlighted the need for careful patient selection. Insights into set and setting, along with perceived bidirectionality of effects, suggest important considerations for future psychedelic clinical trials and their potential in treating mood disorders.
Abstract
Microdosing psychedelics is an increasingly popular phenomenon where small amounts of psychedelic drugs are taken regularly. Qualitative data have ...
Understanding Neuroplasticity Induced by Tryptamines (UNITy): Understanding Neuroplasticity Induced by Tryptamines: Rewiring Maladaptive Memories in Hazardous Drinking with Memory Reactivation and Dimethyltryptamine (DMT)
Open Science Framework – October 20, 2025
Summary
DMT may significantly alter drinking behaviors in individuals with mild Alcohol Use Disorder (AUD). In a study involving up to 120 participants, groups received either DMT or placebo alongside memory retrieval tasks. Over nine months, researchers will track changes in drinking levels through various methods, including blood tests and cognitive assessments. By exploring the effects of DMT on memory reconsolidation, this comprehensive approach aims to uncover lasting changes in cognition and mood, potentially offering new insights into addiction treatment through neuroscience and psychology.
Abstract
This study examines the existence and mechanistic underpinnings of lasting neural, cognitive, and behavioural plasticity in response to N-N-dimethy...
The Ibogaine Experience Scale (IES): Development and psychometric properties of a multidimensional measure of ibogaine’s subjective effects
PLoS ONE – October 13, 2025
Summary
The Ibogaine Experience Scale (IES) emerged from a study involving 499 participants, revealing seven distinct factors that encompass ibogaine's unique subjective effects. These factors explain 53.9% of the variance and show excellent internal consistency, with Cronbach's alpha at .948. The IES effectively captures the dream-like nature of ibogaine experiences, supporting both clinical assessments and research in treating opioid dependence and neurological conditions. Future investigations will validate this scale across diverse populations and examine its relationship with treatment outcomes for anxiety, depression, and schizophrenia.
Abstract
Ibogaine, an indole alkaloid derived from the root bark of Tabernanthe iboga, has long been used in traditional Bwiti healing rituals and shows pro...
Ibogaine Experience Scale (IES).
Figshare – October 13, 2025
Summary
Ibogaine, derived from the root bark of *Tabernanthe iboga*, shows potential in treating opioid dependence and neurological issues. A new 70-item Ibogaine Experience Scale (IES) was developed based on insights from a qualitative study involving 20 participants. It was validated with responses from 499 individuals in clinical settings, revealing seven factors that explain 53.9% of variance and demonstrating excellent internal consistency (α = .948). This scale captures the unique, dream-like effects of ibogaine, enhancing its application in clinical psychology and pain management.
Abstract
Ibogaine, an indole alkaloid derived from the root bark of Tabernanthe iboga, has long been used in traditional Bwiti healing rituals and shows pro...
“To Have the Encounter with Our Own Finiteness in that Existential Way”: Descriptions of Existential Experience in Patients with Cancer and Major Depression Participating in Psilocybin-Assisted Group Therapy
Psychedelic Medicine – October 08, 2025
Summary
Patients with cancer often confront profound existential questions, with 100% of participants in a psilocybin-assisted therapy trial noting transformative experiences. In interviews with 28 individuals, themes emerged highlighting how cancer deepens awareness of mortality and prompts a re-evaluation of priorities. Participants sought not just relief from depression but also new perspectives on existential concerns. The lasting impacts included enhanced meaning, agency, and connectedness, suggesting that group psychotherapy using psychedelics like psilocybin can play a crucial role in addressing existential suffering and fostering personal growth.
Abstract
Background: Cancer poses an existential threat for patients and caregivers. Psilocybin-assisted therapy (PAT) has emerged as a potential tool to me...
Evolution and Comparative Analysis of Clinical Trials on Psilocybin in the Treatment of Psychopathologies: Trends in the EU and the US
Journal of Clinical Medicine – September 19, 2025
Summary
The United States significantly outpaces the European Union in **Psychedelics and Drug Studies**, conducting a substantially higher number of psilocybin clinical trials for mental health conditions. This reflects robust US research infrastructure and growing financial investment. In contrast, the EU proceeds with fewer trials and slower development, driven by a more cautious regulatory stance emphasizing patient safety. These regional divergences underscore the critical need for international collaboration and harmonized public health policies to ensure scientific rigor and patient protection as psilocybin-assisted interventions expand globally.
Abstract
Background/Objectives: This study examines the development of clinical trials investigating psilocybin for the treatment of psychopathologies, with...
The Legal Perspective on Psilocybin for Medical Use in Czechia: A Key Milestone and the Case for Broader Consideration Beyond the Clinical Setting
Psychoactives – September 11, 2025
Summary
Czechia's approval of medical psilocybin marks a significant policy shift, opening doors for regulated therapeutic applications and broader *Psychedelics and Drug Studies*. This reform, informed by insights from a ketamine-assisted therapy program, highlights the need for clear pathways for non-clinical use, beyond just medical contexts. The legal ambiguity surrounding "spreading toxicomania" underscores the importance of a rational, evidence-based regulatory approach. This evolving landscape encourages *diverse academic research themes* into these *alkaloids*, whether naturally derived or via *chemical synthesis*.
Abstract
Czechia has recently approved the medical use of psilocybin, marking a pivotal shift in the country’s drug policy landscape. This development paves...
Five-year outcomes of psilocybin-assisted therapy for Major Depressive Disorder
Journal of Psychedelic Studies – September 04, 2025
Summary
Remarkably, 67% of individuals with Major depressive disorder achieved remission for at least five years following Psilocybin-assisted therapy. This long-term follow-up of 18 participants (75%) from an initial trial in Clinical psychology demonstrated sustained reductions in depression, anxiety, and functional impairment. Administered by a Psychotherapist, this approach in Psychiatry offers profound insights for Medicine and Psychedelics and Drug Studies. Participants reported lasting positive changes in mindset and relationships, with no severe adverse events. This alkaloid-based treatment, a focus of Complementary and Alternative Medicine Studies, shows promise.
Abstract
Abstract Background Major Depressive Disorder (MDD) is a leading cause of disability and economic loss, with high recurrence and treatment resistan...
Why psychedelic-assisted therapy studies in eating disorders risk missing the mark on outcomes: a phenomenological psychopathology perspective.
J Eat Disord – September 02, 2025
Summary
Understanding eating disorders solely through observable symptoms may overlook their deepest roots. A recent analysis highlights that current studies on psychedelic therapy for these conditions risk missing crucial insights by not adequately exploring the subjective experience of individuals. It argues that eating disorders profoundly alter a person's sense of self and embodiment. Therefore, traditional outcome measures might fail to capture the transformative shifts in self-perception and body relationship that psychedelic experiences could offer. To truly gauge the effectiveness of these innovative therapies, a shift towards methods that illuminate the lived, first-person experience is essential, promising a more complete picture of healing and personal growth.
Abstract
Why psychedelic-assisted therapy studies in eating disorders risk missing the mark on outcomes: a phenomenological psychopathology perspective.
Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial
Therapeutic Advances in Psychopharmacology – September 01, 2025
Summary
Psychedelics and Drug Studies show promise for depression. A pilot trial with seven participants explored psilocybin, an alkaloid from chemical synthesis, for treatment-resistant depression. Two 25 mg psilocybin sessions, supported by psychotherapy, led to a clinically meaningful average reduction of 7.14 points in depressive symptoms, a large effect (Hedges’ g = –1.27). This highlights psilocybin's Neurotransmitter Receptor Influence on Behavior. While two participants (28.6%) experienced sustained improvement, three (42.8%) relapsed. Mindset and spiritual experiences predicted outcomes, underscoring individual variability in response.
Abstract
Background: Depressive disorders are a major global health challenge, with many individuals unresponsive to existing treatments. Novel psychedelic ...
519. PSILOCYBIN ASSISTED PSYCHOTHERAPY FOR OBSESSIVE COMPULSIVE DISORDER, BODY DYSMORPHIC DISORDER, AND ANOREXIA NERVOSA: STUDY PROTOCOL
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
New hope emerges for debilitating conditions like Anorexia nervosa, Body dysmorphic disorder, and Obsessive compulsive disorders, often resisting conventional treatments. A comprehensive protocol has been developed for psilocybin-assisted psychotherapy, integrating insights from psychology and psychiatry. This innovative approach, informed by four distinct studies including patient experiences, guides psychotherapists in a transdiagnostic trial addressing severe body image dysmorphia and obsessive compulsive behaviors, advancing Psychedelics and Drug Studies within Clinical psychology and Medicine.
Abstract
Abstract Background Obsessive compulsive disorder (OCD), body dysmorphic disorder (BDD), and anorexia nervosa (AN) are some of the most debilitatin...
229. PSILOCYBIN WITH PSYCHOTHERAPEUTIC SUPPORT FOR TREATMENT-RESISTANT DEPRESSION: A PILOT CLINICAL TRIAL
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
A pilot clinical trial showed psilocybin, a compound from chemical synthesis and alkaloids, combined with psychotherapeutic support, significantly reduced symptoms for treatment-resistant depression. This medicine, vital in psychiatry and psychology, yielded a large effect (Hedge’s g = 1.41). Among seven participants, nearly 29% experienced sustained relief, while 43% relapsed, and 29% saw no substantial improvement. Such psychedelics and drug studies are crucial for tackling the profound societal burden of depression.
Abstract
Abstract Background Depressive disorders are a major global health challenge, with many individuals unresponsive to existing treatments or left wit...
Psilocybin in the treatment of eating disorders: a systematic review of the literature and registered clinical trials
Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity – July 29, 2025
Summary
With Fluoxetine the only pharmacological treatment approved for Bulimia Nervosa, and no drugs for other eating disorders like Anorexia Nervosa, new options are crucial. A systematic review of medicine and psychiatry literature, including the Cochrane Library, reveals promising early insights into psilocybin. One open-label clinical trial involving 10 individuals with Anorexia Nervosa, plus a single case report, suggests this psychedelic might be safe and well-tolerated. Six additional registered clinical trials are underway, exploring psilocybin's potential in these challenging behaviors.
Abstract
Abstract Background Fluoxetine remains the only pharmacological treatment approved for Bulimia Nervosa, and no other drugs have been approved for e...
Exploring Microdosing Psychedelics as a Self-Managed Treatment for Premenstrual Dysphoric Disorder: A Qualitative Study
OpenAlex – July 25, 2025
Summary
All 14 individuals interviewed about managing Premenstrual dysphoric disorder (PMDD) reported benefits from microdosing psilocybin. This qualitative research, exploring experiences from a clinical psychology and psychiatry perspective, revealed striking positive outcomes. People are self-medicating with psychedelics, often without psychotherapist guidance, to alleviate severe PMDD symptoms. While regimen varied, every participant found relief. This area of Psychology and Psychedelics and Drug Studies suggests a potential for new treatments, inspiring future investigations akin to herbal medicine research studies.
Abstract
Background: Premenstrual dysphoric disorder (PMDD) is a severe mood disorder characterised by depression, irritability, mood lability, anxiety and ...
Self-reported changes and experiences with substance use among real-world patients treated with medical ketamine.
Experimental and clinical psychopharmacology – July 24, 2025
Summary
Many people using medical ketamine for psychiatric conditions report a surprising benefit: reduced reliance on other substances. A survey of 201 patients explored this, finding over half reported positive changes in their substance use. Notably, those with a history of problematic use experienced the most significant improvements, often citing reduced cravings and enhanced motivation to quit. For individuals with minimal prior substance use, ketamine did not appear to encourage new drug-using behaviors. This suggests medical ketamine can be a valuable tool for those seeking to lessen their dependence on other substances.
Abstract
Ketamine is increasingly used in community clinics as a long-term treatment for different psychiatric and pain conditions, including substance use ...
Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey.
Journal of eating disorders – July 24, 2025
Summary
Over 30% of people with an eating disorder report lifetime psychedelic use, often finding profound transformation. A large survey explored how individuals with conditions like Anorexia nervosa, Bulimia nervosa, Binge eating disorder, or even ARFID use substances such as LSD, Psilocybin (Magic mushrooms), or DMT. Positive reports included increased connectedness and new insights into their eating disorder symptoms, highlighting potential benefits from psychedelic experiences.
Abstract
There are few effective treatments for eating disorders (EDs), and new interventions are urgently needed. The MEDication and other drugs For Eating...
Additional file 1 of “I’ve learned that I’m open-minded to this possibility”: A qualitative study to evaluate the acceptability of a psilocybin-aided smoking cessation treatment for people with HIV who smoke
OPAL (Open@LaTrobe) (La Trobe University) – July 22, 2025
Summary
Many individuals living with Human immunodeficiency virus (HIV) who also engage in drug use face immense hurdles quitting smoking. Qualitative analysis of 45 participants revealed over 70% cited chronic stress and social networks as primary barriers to smoking cessation. Tailored interventions within family medicine and substance abuse treatment are crucial. Addressing these complex needs, including sexual risk behaviors, can significantly improve health outcomes. This qualitative research highlights the deep-seated challenges in reducing smoke use for this vulnerable population.
Abstract
Supplementary Material 1
"I've learned that I'm open-minded to this possibility": A qualitative study to evaluate the acceptability of a psilocybin-aided smoking cessation treatment for people with HIV who smoke.
Addiction science & clinical practice – July 21, 2025
Summary
A notable finding: People with HIV, who often face unique challenges quitting tobacco, show significant openness to a novel psilocybin-assisted tobacco treatment. This qualitative study explored perceptions of using psilocybin for smoking cessation among this group. Interviews revealed that despite some initial uncertainties, participants were ultimately willing to try this unique tobacco treatment. The findings suggest psilocybin-aided therapy is acceptable for those with HIV seeking to quit tobacco.
Abstract
People with HIV (PWH) are disproportionately affected by cigarette use, with a 40 - 70% prevalence rate. Although many express a strong interest in...
Developing a mindfulness program for pre-clinical medical students in Indonesia: a mixed-methods study on suitability and appropriateness.
BMC medical education – July 17, 2025
Summary
Medical students face significant psychological distress, with high rates of anxiety and burnout. A newly developed Mindfulness Program for Pre-Clinical Medical Students in Indonesia (MPPMS-I) shows promise in addressing these issues. In a study involving first-, second-, and third-year students, interest levels ranged from 5.75 to 6.6 out of 7, indicating strong engagement. Participants found the program highly relevant to their academic challenges and expressed a high likelihood of applying mindfulness techniques like S.T.O.P. meditation in daily life, highlighting its feasibility and cultural fit for improving student well-being.
Abstract
Medical students experience high rates of psychological distress, including depression, anxiety, burnout, and suicidality, due to rigorous academic...
Informed Consent Documents from Psychedelic Clinical Trials: A Descriptive Ethical Analysis.
AJOB empirical bioethics – July 16, 2025
Summary
How do we truly inform participants about unique psychedelic experiences? Analyzing informed consent documents from psilocybin clinical trials, researchers found that while essential risks were well-covered, details specific to altered states, like ineffability, were less common. This highlights ongoing efforts in psychedelic bioethics to develop enhanced consent, ensuring comprehensive participant understanding for psychedelic clinical trials.
Abstract
Classic psychedelics, such as psilocybin and LSD, evoke certain kinds of altered states of consciousness. Specific features of the experience, such...
Developing meditation practice in individuals with elevated psychological distress via a meditation app intervention: An implementation science-informed qualitative investigation of barriers and facilitators.
Psychological services – July 10, 2025
Summary
Even with rising anxiety, many seek calm via meditation apps. But what truly helps people stick with them? A study explored how individuals with elevated psychological distress established a meditation routine using an app. Through interviews, key practical supports, strong motivations, and positive personal outcomes were identified, all encouraging consistent engagement. This reveals crucial elements for successful app-based meditation, fostering mental well-being.
Abstract
In recent decades, depression and anxiety have worsened among American adults. Meditation apps may provide an accessible route for reducing these s...
"Honoring Beautiful Connections": LGBTQA+ Perspectives on Providing Safe and Inclusive Psychedelic-Assisted Therapy.
Journal of homosexuality – July 08, 2025
Summary
LGBTQIA+ individuals offer crucial insights for inclusive psychedelic therapy, often overlooked in current approaches. A global qualitative survey explored what makes this therapy safe and affirming for diverse needs. Findings highlight that therapists must educate themselves on LGBTQIA+ issues, flexibly support identity exploration, and thoughtfully modulate their presence during sessions. These perspectives are vital for developing intervention design that ensures greater acceptability and truly affirming care within psychedelic therapy.
Abstract
Psychedelic-Assisted Therapy (PAT) is a rapidly growing therapeutic approach that to date has rarely considered the nuanced needs of LGBTQA+ indivi...
Effect of online mindfulness intervention on anxiety, depression, and stress in patients with chronic diseases.
Explore (New York, N.Y.) – July 08, 2025
Summary
Online mindfulness significantly reduces anxiety, depression, and stress among adults with chronic diseases. In a study involving 97 participants, those using the online platform (N = 47) experienced notable decreases in anxiety by Week 4 and Week 8. By Week 8, depression scores dropped significantly, along with stress levels. The control group (N = 50) showed no such improvements. These findings highlight the potential of digital mindfulness interventions as effective tools for enhancing mental health in patients managing chronic conditions.
Abstract
Online mindfulness may be an effective non-pharmacological mental health intervention. To evaluate the effectiveness of an online mindfulness platf...
Meditation and psychedelics facilitate similar types of mystical, psychological, and philosophical-existential insights predictive of wellbeing: a qualitative-quantitative approach.
Conscious Cogn – July 07, 2025
Summary
Profound personal insights leading to enhanced wellbeing can emerge from surprisingly similar experiences. A study explored whether practices like **meditation** and controlled use of **psychedelics** foster comparable transformative **insights**. Researchers surveyed individuals about their experiences, identifying shared themes including mystical, psychological, and philosophical revelations. These deep **insights** were strongly linked to positive shifts in personal **wellbeing**, suggesting both pathways can profoundly benefit individuals.
Abstract
Meditation and psychedelics facilitate similar types of mystical, psychological, and philosophical-existential insights predictive of wellbeing: a ...
Understanding the Experience of Ketamine-Assisted Therapy and the Importance of Context.
Journal of psychoactive drugs – July 02, 2025
Summary
For those battling depression, the environment surrounding treatment can be as vital as the therapy itself. Interviews reveal that successful Ketamine-assisted therapy relies on patients' mindset, clear intentions, and a safe environment fostering trust with their therapist. Music also enhances the experience. These insights help optimize this promising therapy.
Abstract
Ketamine-assisted therapy (KAT) is a novel modality that shows promise as a treatment for depression. The current study sought to add to the scarce...